Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Sparsentan Versus Irbesartan in Pediatric Patients With FSGS.
Journal: Kidney international reports
Published: February 04, 2026
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: June 26, 2025
Framework for precision medicine in focal segmental glomerulosclerosis: Translation of sparsentan-responsive genes in a rat model to kidney disease associated proteins in biofluids.
Journal: medRxiv : the preprint server for health sciences
Published: March 10, 2025
Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: May 29, 2024
Sparsentan and kidney protection: improved medullary oxygenation? - Authors' reply.
Journal: Lancet (London, England)
Published: May 26, 2024
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy.
Journal: Expert review of clinical immunology
Published: February 16, 2024
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Journal: The New England journal of medicine
Published: November 03, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: September 29, 2023
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
Journal: Kidney international reports
Published: September 12, 2023
Status of current trials and potential future trials with sparsentan.
Journal: Expert opinion on emerging drugs
Published: July 19, 2023
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Journal: Lancet (London, England)
Published: February 28, 2023
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
Journal: Kidney international reports
Published: February 03, 2023
Last Updated: 09/26/2026